16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Preface on Lung Cancer Management—The Next Decade

      editorial
      , BSc (Hons), MBBS (Hons) (Lond), MD (Res) (Lond), FRCSEd, FCCP
      Annals of Translational Medicine
      AME Publishing Company
      Robots, lung cancer, liquid biopsy, artificial intelligence, 3D printing

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The management of lung cancer has evolved very rapidly in the past decade. The introduction of targeted and immunotherapies have significantly improved outcomes especially in advanced stage disease (1), endobronchial technology to improve early diagnostic yields (2), robotic surgery to perform challenging surgery in more precise manner (3), and liquid biopsies to diagnose and guide treatments. However, these past great leaps in lung cancer management, as Sir Winston Churchill once said, “… is not the end. It is not even the beginning of the end. But it is perhaps, the end of the beginning.” In this special series of “Lung Cancer Management—The Next Decade”, we have invited some of the top clinician scientists in the field, many of them pioneers and trailblazers in their topics, to provide us with their unique perspectives. The articles cover the latest developments in: (I) the use of circulating tumour DNA and the potentials it holds [Lam et al. (4)]; (II) the current and future technologies of using robotic bronchoscopy [Ho et al. (5)] and cone beam computed tomography (CT) scan for accurate tissue biopsy acquisition [Verhoeven et al. (6)]; (III) the state of the art in non-invasive and minimally invasive surgical approaches to treat lung cancer by transbronchial ablation therapies [Chan et al. (7)] and uniportal robotic surgery [Gonzalez-Rivas et al. (8)]; (IV) the current use of targeted therapy with preview to how it might change in the next decade [Li et al. (9)]; and (V) other technologies such as artificial intelligence [Bardoni et al. (10)] and 3D printing [Aravena et al. (11)] that could revolutionize how lung cancer is managed. We hope you will enjoy reading this special series, where leading clinician scientists dare to push the boundaries and dream of what might become standard care in their own sub-specialty or area of research interest in the next golden decade. Calvin S. H. Ng Supplementary The article’s supplementary files as 10.21037/atm-2024-01

          Related collections

          Most cited references11

          • Record: found
          • Abstract: not found
          • Article: not found

          Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Uniportal pure robotic-assisted thoracic surgery—technical aspects, tips and tricks

            The uniportal access for robotic thoracic surgery presents itself as a natural evolution of minimally invasive thoracic surgery (MITS). It was developed by surgeons who pioneered the uniportal video-assisted thoracic surgery (U-VATS) in all its aspects following the same principles of a single incision by using robotic technology. The robotic surgery was initially started as a hybrid procedure with the use of thoracoscopic staplers by the assistant. However, due to the evolution of robotic modern platforms, the staplers can be nowadays controlled by the main surgeon from the console. The pure uniportal robotic-assisted thoracic surgery (U-RATS) is defined as the robotic thoracic surgery performed through a single intercostal (ic) incision, without rib spreading, using the robotic camera, robotic dissecting instruments and robotic staplers. There are presented the advantages, difficulties, the general aspects and specific considerations for U-RATS. For safety reasons, the authors recommend the transition from multiportal-RATS through biportal-RATS to U-RATS. The use of robotic dissection and staplers through a single incision and the rapid undocking with easy emergent conversion when needed (either to U-VATS or to thoracotomy) are safety advantages over multi-port RATS that cannot be overlooked, offering great comfort to the surgeon and quick and smooth recovery to the patient.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review

              Background and Objective The adoption of targeted therapy and immunotherapy has revolutionised the treatment landscape of non-small cell lung cancer. For early staged disease, incorporation of targeted therapy and immunotherapy has recently been demonstrated to reduce recurrence. Development of targeted therapies in advanced lung cancer is driven by advanced genomic sequencing techniques, better understanding of drug resistance mechanisms, and improved drug designs. The list of targetable molecular alteration is continuously expanding, and next generation molecular therapies have shown promise in circumventing drug resistance. Lung cancer patients may achieve durable disease control with immune checkpoint inhibitors however most patients develop immunotherapy resistance. A wide spectrum of resistance mechanisms, ranging from impaired T-cell activation, presence of coinhibitory immune checkpoints, to immunosuppressive tumour microenvironment, have been proposed. A multitude of novel immunotherapy strategies are under development to target such resistance mechanisms. This review aims to provide a succinct overview in the latest development in targeted therapy and immunotherapy for NSCLC management. Methods We searched all original papers and reviews on targeted therapy and immunotherapy in non-small cell lung cancer (NSCLC) using PubMed in June 2022. Search terms included “non-small cell lung cancer”, “targeted therapy”, “immunotherapy”, “EGFR”, “ALK”, “ROS1”, “BRAF V600E”, “MET”, “RET”, “KRAS”, “HER2”, “ERBB2”, “NRG1”, “immune checkpoint”, “PD-1”, “PD-L1”, “CTLA4”, “TIGIT”, “VEGF”, “cancer vaccine”, “cellular therapy”, “tumour microenvironment”, “cytokine”, and “gut microbiota”. Key Content and Findings We first discuss the incorporation of targeted therapy and immunotherapy in early staged NSCLC. This includes the latest clinical data that led to the approval of neoadjuvant immunotherapy, adjuvant immunotherapy and adjuvant targeted therapy for early staged NSCLC. The second section focuses on targeted therapy in metastatic NSCLC. The list of targetable alteration now includes but is not limited to EGFR, ALK, ROS1, BRAF V600E, MET exon 14 skipping, RET, KRAS G12C, HER2 and NRG1. Potential drug resistance mechanisms and novel therapeutics under development are also discussed. The third section on immunotherapy in metastatic NSCLC, covers immunotherapy that are currently approved [anti-PD-(L)1 and anti-CTLA4], and agents that are under active research (e.g., anti-TIGIT, cancer vaccine, cellular therapy, cytokine and other TME modulating agents). Conclusions This review encompasses the latest updates in targeted therapy and immunotherapy in lung cancer management and discusses the future direction in the field.
                Bookmark

                Author and article information

                Journal
                Ann Transl Med
                Ann Transl Med
                ATM
                Annals of Translational Medicine
                AME Publishing Company
                2305-5839
                2305-5847
                07 April 2024
                10 June 2024
                : 12
                : 3
                : 41
                Affiliations
                [1]Department of Surgery, The Chinese University of Hong Kong, Hong Kong , China.
                Author notes
                Article
                atm-12-03-41
                10.21037/atm-2024-01
                11193569
                38911556
                41525b0a-18ef-40b9-9c93-a8375c941ec4
                2024 Annals of Translational Medicine. All rights reserved.

                Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

                History
                : 19 January 2024
                : 30 January 2024
                Categories
                Editorial

                robots,lung cancer,liquid biopsy,artificial intelligence,3d printing

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content5,860

                Most referenced authors76